Adrion, Christine (Gastwissenschaftlerin)


Peer-reviewed journal articles

  • Spies CD, Paul N*, Adrion C*, Berger E, Busse R, Kraufmann B, Marschall U, Rosseau S, Denke C, Krampe H, Dähnert E, Mansmann U, Weiss B; on behalf of the ERIC study group.
    Effectiveness of an intensive care telehealth-program to improve process quality (ERIC): a multicentre stepped wedge cluster randomised controlled trial.
    Intensive Care Med 
    2023; 49(2):191-204. DOI: 10.1007/s00134-022-06949-x.
    *Shared second authorship
  • Feil K*, Adrion C*, Boesch S, Steiner KM, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Timmann D, Naumann I, Mansmann U, Strupp M; ALCAT Study Group.
    Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    JAMA Network Open
    2021; 4(12):e2135841. DOI: 10.1001/jamanetworkopen.2021.35841.
    *Shared first authorship

  • Renz BW*, Adrion C*, Klinger C, Ilmer M, D'Haese J, Buhr H-J, Mansmann U, Werner J; PyloResPres study group.
    Pylorus resection versus pylorus preservation in pancreatoduodenectomy (PyloResPres): study protocol and statistical analysis plan for a German multicentre, single-blind, surgical, registry-based randomised controlled trial.
    BMJ Open 2021; 11:e056191. DOI: 10.1136/bmjopen-2021-056191. 
    Preprint available at medRxiv 2021.08.05.21260575; DOI: https://doi.org/10.1101/2021.08.05.21260575.
    *Shared first authorship
  • Behning C, Fleckenstein M, Pfau M, Adrion C, Goerdt L, Lindner M, Schmitz-Valckenberg S, Holz FG, Schmid M.
    Modeling of Atrophy Size Trajectories: Variable Transformation, Prediction and Age-of-Onset Estimation.
    BMC Med Res Methodol 2021; 21(1):170. DOI: https://doi.org/10.1186/s12874-021-01356-0.

  • Adrion C*, Weiss B*, Paul N, Berger E, Busse R, Marschall U, Caumanns J, Rosseau S, Mansmann U, Spies CD; ERIC study group.
    Enhanced Recovery after Intensive Care (ERIC): study protocol for a stepped wedge cluster randomized controlled trial to evaluate the effectiveness of a critical care telehealth program on process quality and functional outcomes.
    BMJ Open 2020; 10:e036096. DOI: 10.1136/bmjopen-2019-036096.
    Preprint available at medRxiv 2020.01.25.19013565; DOI: https://doi.org/10.1101/2020.01.25.19013565.
    *Shared first authorship
  • Bayer O*, Adrion C*, Al Tawil A, Mansmann U, Strupp M; PROVEMIG investigators.
    Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).
    Trials 2019 Dec 30; 20(1):813.
    *Shared first authorship

  • Gensichen J*, Schultz S*, Adrion C, Schmidt K, Schauer M, Lindemann D, et al.
    Effect of a combined brief narrative exposure therapy with case management versus treatment as usual in primary care for patients with traumatic stress sequelae following intensive care medicine: study protocol for a multicenter randomized controlled trial (PICTURE).
    2018; 19(1):480

  • Feil K, Adrion C, Teufel J, Bösch S, Claassen C, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Uslar E, Warrenburg B, Berger I, Naumann I, Bayer O, Müller HH, Mansmann U, Strupp M.
    Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    BMC Neurology
    2017; 17(1):7

  • Adrion C, Fischer CS, Wagner J, Mansmann U, Strupp M; on behalf of the BEMED study group.
    Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
    BMJ 2016; 352:h6816. DOI: http://dx.doi.org/10.1136/bmj.h6816

  • Gross L, Theiss HD, Grabmaier U, Adrion C, Mansmann U, Sohn HY, Hoffmann E, Steinbeck G, Franz WM, Brenner C.
    Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction – Long-term results of the SITAGRAMI Trial.
    Int J Cardiol 2016; 215:441-445.

  • Brenner C, Adrion C, Grabmaier U, Theisen D, von Ziegler F, Leber A, Becker A, Sohn HY, Hoffmann E, Mansmann U, Steinbeck G, Franz WM, Theiss HD.
    SITAgliptin plus GRanulocyte colony-stimulating factor in patients suffering from Acute Myocardial Infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial).
    Int J Cardiol 2016; 205:23-30.

  • Bender A, Adrion C, Fischer L, Huber M, Jawny K, Straube A, Mansmann U.
    Long-term rehabilitation in patients with acquired brain injury: A randomized controlled trial of an intensive, participation-focused outpatient treatment program [Langzeitrehabilitation von Patienten mit erworbenen Hirnschädigungen: Eine randomisierte kontrollierte Studie zu einem intensiven teilhabeorientierten ambulanten Therapieprogramm].
    Dtsch Arztebl Int
    2016; 113:634-41

  • Hüfner K, Frenzel C, Kremmyda O, Adrion C, Bardins S, Glasauer S, Brandt T, Strupp M.
    Esophoria or esotropia in adulthood – a sign of cerebellar dysfunction?
    J Neurol 2015; 262(3):585-92.

  • Schwab F, Ingrisch M, Marcus R, Bamberg F, Hildebrand K, Adrion C, Gliemi C, Nikolaou K, Reiser M, Theisen D.
    Tracer kinetic modeling in myocardial perfusion quantification using magnetic resonance imaging.
    Magnetic Resonance in Medicine
    2015; 73(3):1206-15

  • Neugebauer H, Adrion C, Glaser M, Strupp M.
    Long-term changes of central ocular motor signs in patients with vestibular migraine.
    Eur Neurol 2013; 69(2):102-107.

  • Adrion C, Mansmann U.
    Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: An example from a vertigo phase III study with longitudinal count data as primary endpoint.
    BMC Medical Research Methodology
    2012; 12(1):137
    . DOI: 10.1186/1471-2288-12-137.

  • Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, Strupp M, Jahn K.
    4-aminopyridine and cerebellar gait – a retrospective case series.
    J Neurol 2012; 259(11):2491-3.

  • Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz-Valckenberg S, Bindewald-Wittich A, Keilhauer CN, Renner AB, Mackensen F, Mößner A, Pauleikhoff D, Adrion C, Mansmann U, Scholl HP, Holz FG, Weber BHF.
    A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene.
    Invest Ophthalmol Vis Sci
    2012; 53(4):2112-2118

  • Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K.
    A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
    Neurology 2011; 77(3):269-75.

  • Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Visvalingam S, Göbel AP, Mössner A, von Strachwitz CN, Mackensen F, Pauleikhoff D, Wolf S, Mansmann U, Holz FG; FAM Study Group.
    Progression of age-related geographic atrophy: role of the fellow eye.
    Invest Ophthalmol Vis Sci
    2011; 52(9):6552-7

  • Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M.
    High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series.
    Eur Arch Otorhinolaryngol
    2011; 268(8):1237-40

  • Brinkmann CK, Adrion C, Mansmann U, Schmitz-Valckenberg S, Holz FG.
    Clinical characteristics, progression and risk factors of geographic atrophy.
    2010; 107(11):999-1006

  • Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Krämer I, Eter N, Helb HM, Brinkmann CK, Charbel Issa P, Mansmann U, Holz FG.
    Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration.
    Invest Ophthalmol Vis Sci
    2010; 51(8):3846-52

  • Fleckenstein M*, Adrion C*, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HP, Mansmann U, Holz FG; FAM Study Group.
    Concordance of disease progression in bilateral geographic atrophy due to AMD.
    Invest Ophthalmol Vis Sci
    2010; 51(2):637-42
    *Shared first authorship 
  • Scholl HP, Fleckenstein M, Fritsche LG, Schmitz-Valckenberg S, Göbel A, Adrion C, Herold C, Keilhauer CN, Mackensen F, Mössner A, Pauleikhoff D, Weinberger AW, Mansmann U, Holz FG, Becker T, Weber BH.
    CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD.
    PLoS One
    2009; 4(10):e7418

  • Hüfner K, Barresi D, Glaser M, Linn J, Adrion C, Mansmann U, Brandt T, Strupp M.
    Vestibular paroxysmia: diagnostic features and medical treatment.
    2008; 71(13):1006-14

  • Mansmann U, Crispin A, Henschel V, Adrion C, Augustin V, Birkner B, Munte A.
    Epidemiology and Quality Control of 245000 Outpatient Colonoscopies.
    Dtsch Arztebl
    2008; 105(24):434-40

Group authorship

Turner EL, Platt AC, Gallis JA, Tetreault K, Easter C, McKenzie JE, Nash S, Forbes AB, Hemming K, on behalf of the CRT Binary Outcome Reporting Group.
Completeness of reporting and risks of overstating impact in cluster randomised trials: a systematic review.
The Lancet Global Health 2021; 9(8):e1163-e8. DOI: https://doi.org/10.1016/S2214-109X(21)00200-X

Letter to the Editor

Adrion C, Strupp M, Mansmann U. Lessons learned from a recent superiority trial on intratympanic injections in refractory unilateral Meniere’s disease? Commentary on Patel et al.
Rapid Response (electronic letter to the editor), 12 March 2017,

Adrion C, Mansmann U. Question about primary outcome definition in the BEMED trial: Author response.
BMJ Rapid Response (electronic letter to the editor), 24 November 2017,

Stand: 12/2022